CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma-Reference-Cited by-同舟云学术

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Published:2017-09 Issue:9 Volume:25 Page:2214-2224
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Heczey Andras,Louis Chrystal U.,Savoldo Barbara,Dakhova Olga,Durett April,Grilley Bambi,Liu Hao,Wu Mengfeng F.,Mei Zhuyong,Gee Adrian,Mehta Birju,Zhang Huimin,Mahmood Nadia,Tashiro Haruko,Heslop Helen E.,Dotti Gianpietro,Rooney Cliona M.,Brenner Malcolm K.

Funder

National Institutes of Health

Solving Kids’ Cancer

Kids’ Cancer Research Foundation

The EVAN Foundation

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference43 articles.

1. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma;Yu;N. Engl. J. Med.,2010

2. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission;Cheung;J. Clin. Oncol.,2012